Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Azacitidine and Lenalidomide in AML
NCT01016600Phase 2Completed
- Sponsor
- Washington University School of Medicine
- Start
- Apr 2010
- Primary completion
- Nov 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of lenalidomide, azacitidine in acute myeloid leukemia (AML), sponsored by Washington University School of Medicine. Started Apr 2010; status: completed.
02
Drugs
lenalidomideazacitidine
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT01016600.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01016600.